Abstract

Extracted from text ... 47 SA Pharmaceutical Journal - July 2006
DRUG INFO
Information supplied by
Amayeza Info Services
Tel : (011) 678 2332
Eplerenone (Inspra(r)) -
Reduces risk of
cardiovascular death after
acute MI
Approved indication
Eplerenone is indicated to reduce the
risk of cardiovascular death in stable
patients with left ventricular dysfunction
(ejection fraction =?40%) and clinical
evidence of heart failure after acute
myocardial infarction (MI).
Mode of action
Eplerenone is a selective aldosterone
receptor antagonist. It binds to the
mineralocorticoid receptor and blocks
the binding of aldosterone. Eplerenone
is similar in structure to spironolactone
but has a lower affinity for the ..